Buket Yilmaz Bulbul

Buket Yilmaz Bulbul


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2024 in Endocrine Pathology
Verified
Journal Article
Open access
PDF file
MBMerve Bagıs
Merve Bagıs
NCNuray Can
Nuray Can
NSNecdet Sut
Necdet Sut
ETEbru Tastekin
Ebru Tastekin
EEEzgi Genc Erdogan
Ezgi Genc Erdogan
IUInci Usta
Inci Usta
Significant interobserver variabilities exist for Bethesda category III: atypia of undetermined significance (AUS) of The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). Thus, subcategorization of AUS including AUS “nuclear” and AUS “other” is proposed in the recent 3rd edition of TBSRTC. This study investigated the impact of the nuclear features/architectural features/nuclear score (NS) (3-tiered)/subcategories and subgroups on risk of malignancy (ROM) in thyroid fine-needle aspirations (FNA). 6940 FNAs were evaluated. 1224 (17.6%) cases diagnosed as AUS were reviewed, and 240 patients (initial FNAs of 260 nodules and 240 thyroidectomies) were included. Subcategories and subgroups were defined according to TBSRTC 2nd and 3rd editions. Histological diagnostic groups included nonneoplastic disease, benign neoplasm, low-risk neoplasm, and malignant neoplasm. Overall, ROM was 30.7%. ROM was significantly higher in FNAs with nuclear overlapping (35.5%), nuclear molding (56.9%), irregular contours (42.1%), nuclear grooves (74.1%), chromatin clearing (49.4%), and chromatin margination (57.7%), and these features were independent significant predictors for malignancy. FNAs with NS3 had significantly higher ROM (64.2%). Three-dimensional groups were significantly more frequent in malignant neoplasms (35.7%). ROM was significantly higher in AUS-nuclear subcategory (48.2%) and in AUS-nuclear and architectural subcategory (38.3%). The highest ROM was detected in AUS-nuclear1 subgroup (65.2%). ROM was significantly higher in the group including AUS-nuclear and AUS-nuclear and architectural subcategories, namely “high-risk group” than the group including other subcategories, namely “low-risk group” (42.0%vs 13.9%). In conclusion, subcategorization may not be the end point, and nuclear scoring and evaluation of architectural patterns according to strict criteria may provide data for remodeling of TBSRTC categories.

26 January 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
NCNuray Can
Nuray Can
BBBuket Yilmaz Bulbul
Buket Yilmaz Bulbul
FOFiliz Ozyilmaz
Filiz Ozyilmaz
NSNecdet Sut
Necdet Sut
MMMeltem Ayyıldız Mercan
Meltem Ayyıldız Mercan
HGHakan Gürkan
Hakan Gürkan
(1) Introduction: The impact of multifocality/bilaterality on the prognosis of papillary thyroid carcinoma (PTC) is a matter of debate. In order to clarify this debate, several studies have attempted to identify additional parameters associated with poor prognosis, including total tumor diameter (TTD), in the context of multifocal PTCs. In this context, this study was carried out to investigate the impact of TTD on tumor recurrence and lymph node metastasis (LNM) in PTCs. (2) Materials and Methods: The sample of this single-center retrospective study consisted of 706 patients diagnosed with PTC. TTD was calculated as the sum of the largest diameters of tumor foci in multifocal tumors. The resulting TTDs were grouped into TTDs ≤ 10 mm, TTDs > 10 mm, TTDs ≤ 20 mm, and TTDs > 20 mm, using 10 mm and 20 mm as cutoff values. (3) Results: There was no significant difference between multifocal papillary microcarcinomas (PTMCs) with a TTD of >10 mm and unifocal PTCs with a primary tumor diameter (PTD) of >10 mm except for advanced age and lymphovascular invasion (LVI). In addition, perineural invasion (PNI) and TTD > 10 mm were found to be significant risk factors for LNM, and PNI, TTD > 10 mm, TTD > 20 mm, and bilaterality were found to be significant risk factors for recurrence. LVI, and TTD > 10 mm were found to be independent significant predictors for recurrence, and LVI and extrathyroidal extension (ETE) were found to be independent significant predictors for LNM. (4) Conclusions: Considering TTD > 10 mm in recurrence risk categorization models and adopting a clinical approach that takes into account multifocal PTMCs with TTD > 10 mm along with unifocal PTCs with PTD > 10 mm may be more useful in terms of clinical management of the disease.

25 March 2025 in Medicina
Verified
Journal Article
Open access
PDF file
SCSerpil Yanık Colak
Serpil Yanık Colak
BABurak Andac
Burak Andac
EÖEray Özgün
Eray Özgün
BBBuket Yilmaz Bulbul
Buket Yilmaz Bulbul
MOMine Okur
Mine Okur
Mehmet CelikMehmet Celik
Mehmet Celik
Background and Objectives: MG53 is a myokine/cardiokine involved in membrane repair. Some preclinical studies suggest that it is associated with insulin resistance. Metabolic syndrome (MS) is manifested by dyslipidemia, hypertension (HT), visceral obesity, hyperinsulinism, and glucose intolerance. We aimed to evaluate the relationship between the MG53 protein and MS and its components. Materials and Methods: This study was conducted among 64 patients with MS and 64 age- and sex-matched healthy participants. MG53 levels were measured using Human-MG53, a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Cat# CSB-EL024511HU, Alfagen laboratory supplies, Cusabio, Bornova, İzmir.). Results: There was no significant connection between serum MG53 levels and the presence of MS (p = 0.969). We found no correlation between serum MG53 levels and the presence of HT, weight, waist circumference, body mass index, HDL-C, fasting blood glucose, and HbA1c levels. Conclusions: This study’s results suggest no association between serum MG53 levels and MS parameters in the studied ethnic population. Due to the limited number and controversy of available studies on this subject, our findings may provide perspective for conducting studies with more diverse populations to obtain more comprehensive results.

12 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BBBuket Yilmaz Bulbul
Buket Yilmaz Bulbul
NCNuray Can
Nuray Can
NINuri Işler
Nuri Işler
BABurak Andac
Burak Andac
EYEsra Zeynep Yucesan
Esra Zeynep Yucesan
Mehmet CelikMehmet Celik
Mehmet Celik
Background/Objectives: Diagnostic criteria for non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) have changed twice since 2016, most visibly in the tolerance for true papillae and in the role of molecular findings. We evaluated historical NIFTPs under the original and subsequent frameworks and related framework-specific classification to long-term outcomes. Methods: In this single-center, retrospective cohort (surgery 2007–2016), archival slides of 79 historical NIFTPs with linked longitudinal follow-up were independently re-reviewed in 2026 by two pathologists without knowledge of long-term outcomes or molecular results; their framework-specific classifications were concordant in all cases. Reasons for failure to retain the diagnosis across all frameworks were classified as criterion-dependent, criterion-independent, or technical. Outcomes were compared with 56 infiltrative and 39 invasive encapsulated follicular-variant papillary thyroid carcinomas (FVPTCs) from the same institution. Results: Thirty-six tumors (45.6%; 95% CI, 34.3–57.2%) qualified as NIFTP under all frameworks. Retention was 47/79 (59.5%; 95% CI, 47.9–70.4%) under the original 2016 criteria, 37/79 (46.8%; 95% CI, 35.5–58.4%) under the 2018 consensus primary criteria, and 46/79 (58.2%; 95% CI, 46.6–69.2%) under WHO 2022. Ten tumors with well-formed true papillae occupying <1% qualified under 2016 and WHO 2022 but not under the 2018 criteria. One additional BRAF V600E-positive tumor had no well-formed papillae, an entirely follicular growth pattern, and a nuclear score of 3; it fulfilled the 2016 and 2018 primary morphologic criteria but was excluded under WHO 2022 because BRAF V600E was detected. Criterion-independent discordance between the historical classification and contemporary re-review accounted for 28/79 tumors (35.4%; 95% CI, 25.0–47.0%). During a median follow-up of 132 months, no incident structural events were observed among historical NIFTPs (0/64; upper 95% CI, 5.6%), and none of 36 with examined lymph nodes had nodal metastasis, whereas nodal metastasis at surgery (4/27) and the only incident structural recurrence occurred among invasive encapsulated FVPTCs. Conclusions: Framework-specific retention ranged from 46.8% to 59.5%, driven mainly by the papilla criterion and, in one molecularly discordant case, BRAF V600E status. Most diagnostic loss reflected criterion-independent discordance identified on contemporary dual-pathologist slide re-review. No incident structural events were observed among outcome-evaluable historical NIFTPs during a median follow-up of 11 years.